Abstract We congratulate Halpin and colleagues1 on their work to identify residual symptoms in patients with microbiological recovery from COVID‐19. The prevalence of residual symptoms in their cohort is much… Click to show full abstract
Abstract We congratulate Halpin and colleagues1 on their work to identify residual symptoms in patients with microbiological recovery from COVID‐19. The prevalence of residual symptoms in their cohort is much higher than estimates of 35% among out‐patient, 2 but comparable with recent cohorts of hospitalized patients (87%).3 This article is protected by copyright. All rights reserved.
               
Click one of the above tabs to view related content.